Kymera Therapeutics, Inc. announced on April 22, 2025, that it recently initiated dosing in its BroADen Phase 1b clinical trial. This trial is evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic dermatitis (AD).
The company expects to report data from the BroADen trial in the fourth quarter of 2025. This advancement follows the completion of SAD/MAD dosing and follow-up in the KT-621 Phase 1 healthy volunteer trial, with data from that study expected in June 2025.
The BroADen trial is a single-arm, open-label study in approximately 20 adult AD patients, assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity. The key objective is to demonstrate a dupilumab-like effect on reducing Th2 biomarkers in blood and active AD skin lesions. Two parallel Phase 2b trials in AD and asthma are planned to start in the fourth quarter of 2025 and the first quarter of 2026, respectively.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.